Pharmaceutical governance system for costly drugs through human rights due diligence Post date 11 November 2025 ← Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements → Collective international action to increase access to costly drugs: pooled procurement and equity based tiered pricing